ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi Signs On Two New Partners

by Lisa M. Jarvis
June 14, 2010 | APPEARED IN VOLUME 88, ISSUE 24

Sanofi-Aventis will work with Ascenta Therapeutics to develop orally active small-molecule drug candidates that block a protein-protein interaction that suppresses tumor-cell death. Ascenta could receive up to $398 million if compounds blocking the interaction between the proteins HDM2 and p53 reach the market. In a separate deal, Sanofi’s vaccines division will work with French biotech Vivalis to develop fully human monoclonal antibodies against a range of infectious disease targets. Vivalis gets $3.6 million up front, research funding, and up to $42 million for each infectious disease target pursued.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment